Armistice Capital’s Bluejay Diagnostics BJDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-32,750
Closed -$157K – 368
2026
Q2
$157K Buy
+32,750
New +$339K ﹤0.01% 312
2026
Q1
– Sell
-4,063
Closed -$43.4K – 284
2025
Q4
$43.4K Buy
+4,063
New +$107K ﹤0.01% 355
2024
Q2
– Sell
-28
Closed -$141K – 274
2024
Q1
$141K Buy
28
+24
+600% +$132K ﹤0.01% 300
2023
Q4
$29.6K Buy
+4
New +$86.7K ﹤0.01% 266

Other funds holding BJDX

Armistice Capital's BJDX Position: Q3 2026 in Review

Armistice Capital sold out of Bluejay Diagnostics (BJDX) in Q3 2026, closing a stake of 32,750 shares — an estimated $157K sold.

Armistice Capital first reported a position in BJDX in Q4 2023 and held it in 4 quarters. The position peaked at $157K in Q2 2026. 13 funds tracked by Wall St. Rank hold BJDX as of Q3 2026.

  • Armistice Capital reported no remaining Bluejay Diagnostics position as of Q3 2026 after selling out during the quarter.
  • Armistice Capital sold 32,750 Bluejay Diagnostics shares in Q3 2026, an estimated $157K.
  • Armistice Capital first reported a position in Bluejay Diagnostics in Q4 2023 and held it in 4 quarters.
  • Armistice Capital's Bluejay Diagnostics position peaked at $157K in Q2 2026.
  • 13 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q3 2026.

Based on Armistice Capital's 13F filing for Q3 2026, filed 16 Nov 2026.